Pulmonary Complications of Liver Disease

Chapter

Keywords

Respiratory failure Hepato-pulmonary syndrome Porto-pulmonary hypertension Restrictive lung disease Postoperative ventilation Pulmonary function test 

References

  1. 1.
    Przybyłowski T, Krenke R, Fangrat A, et al. Gas exchange abnormalities in patients listed for liver transplantation. J Physiol Pharmacol. 2006;57(Suppl 4):313–23.PubMedGoogle Scholar
  2. 2.
    Agustí AG, Roca J, Bosch J, Rodriguez-Roisin R. The lung in patients with cirrhosis. J Hepatol. 1990;10:251–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Mohamed R, Freeman JW, Guest PJ, et al. Pulmonary gas exchange abnormalities in liver transplant candidates. Liver Transpl. 2002;8:802–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Yao EH, Kong BC, Hsue GL, et al. Pulmonary function changes in cirrhosis of the liver. Am J Gastroenterol. 1987;82:352–4.PubMedGoogle Scholar
  5. 5.
    Yigit IP, Hacievliyagil SS, Seckin Y, et al. The relationship between severity of liver cirrhosis and pulmonary function tests. Dig Dis Sci. 2008;53:1951–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Martínez GP, Barberà JA, Visa J, et al. Hepatopulmonary syndrome in candidates for liver transplantation. J Hepatol. 2001;34:651–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Martínez-Palli G, Gómez FP, Barberà JA, et al. Sustained low diffusing capacity in hepatopulmonary syndrome after liver transplantation. World J Gastroenterol. 2006;12:5878–83.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Castaing Y, Manier G. Hemodynamic disturbances and VA/Q matching in hypoxemic cirrhotic patients. Chest. 1989;96:1064–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Naeije R, Halleman R, Mols P, Melot C. Hypoxic pulmonary vasoconstriction in liver cirrhosis. Chest. 1981;80:570–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Degano B, Mittaine M, Guénard H, et al. Nitric oxide and carbon monoxide lung transfer in patients with advanced liver cirrhosis. J Appl Physiol. 2009;107:139–43.PubMedCrossRefGoogle Scholar
  11. 11.
    Andrivet P, Cadranel J, Housset B, et al. Mechanisms of impaired arterial oxygenation in patients with liver cirrhosis and severe respiratory insufficiency. Effects of indomethacin. Chest. 1993;103:500–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Kim BJ, Lee SC, Park SW, et al. Characteristics and prevalence of intrapulmonary shunt detected by contrast echocardiography with harmonic imaging in liver transplant candidates. Am J Cardiol. 2004;94:525–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Rodríguez-Roisin R, Krowka MJ, Hervé P, et al. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J. 2004;24:861–80.PubMedCrossRefGoogle Scholar
  14. 14.
    Hourani JM, Bellamy PE, Tashkin DP, et al. Pulmonary dysfunction in advanced liver disease: frequent occurrence of an abnormal diffusing capacity. Am J Med. 1991;90:693–700.PubMedCrossRefGoogle Scholar
  15. 15.
    Wagner PD, Rodriguez-Roisin R. Clinical advances in pulmonary gas exchange. Am Rev Respir Dis. 1991;143:883–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Rodríguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome—a liver-induced lung vascular disorder. N Engl J Med. 2008;358:2378–87.PubMedCrossRefGoogle Scholar
  17. 17.
    Matsubara O, Nakamura T, Uehara T, Kasuga T. Histometrical investigation of the pulmonary artery in severe hepatic disease. J Pathol. 1984;143:31–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Moyer K, Balistreri W. Hepatobiliary disease in patients with cystic fibrosis. Curr Opin Gastroenterol. 2009;25:272–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352:1992–2001.PubMedCrossRefGoogle Scholar
  20. 20.
    Fairbanks KD, Tavill AS. Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol. 2008;103:2136–41.PubMedCrossRefGoogle Scholar
  21. 21.
    Elborn JS. Cystic fibrosis. Lancet. 2016;388:2519–31.  https://doi.org/10.1016/S0140-6736(16)00576-6. [Epub ahead of print].CrossRefPubMedGoogle Scholar
  22. 22.
    Nick JA, Chacon CS, Brayshaw SJ, et al. Effects of gender and age of diagnosis on disease progression in long-term cystic fibrosis survivors. Am J Respir Crit Care Med. 2010;182(5):614–26.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Farrell PM, Rosensteinn BJ, White TB, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008;153:S4–14.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Rodman DM, Polis JM, Heltshe SL, et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med. 2005;171(6):621.PubMedCrossRefGoogle Scholar
  25. 25.
    Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med. 2006;173:475–82.PubMedCrossRefGoogle Scholar
  26. 26.
    Wilschanski M. Patterns of gastrointestinal disease associated with mutations of CFTR. Curr Gastroenterol Rep. 2008;10:316–23.PubMedCrossRefGoogle Scholar
  27. 27.
    Feranchak AP, Sokol RJ. Cholangiocyte biology and cystic fibrosis liver disease. Semin Liver Dis. 2001;21:471–88.PubMedCrossRefGoogle Scholar
  28. 28.
    Lindblad A, Glaumann H, Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology. 1998;27:166–74.PubMedCrossRefGoogle Scholar
  29. 29.
    Desmond CP, Wilson J, Bailey M, et al. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid. Liver Int. 2007;27:1402–8.PubMedGoogle Scholar
  30. 30.
    Gooding I, Dondos V, Gyi KM, et al. Variceal hemorrhage and cystic fibrosis: outcomes and implications for liver transplantation. Liver Transpl. 2005;11:1522–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Siano M, De Gregorio F, Boggia B, et al. Ursodeoxycholic acid treatment in patients with cystic fibrosis at risk for liver disease. Dig Liver Dis. 2010;42:428–31.PubMedCrossRefGoogle Scholar
  32. 32.
    Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev. 2010;23:299–323.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Black SM, Woodley FW, Tumin D, et al. Cystic fibrosis associated with worse survival after liver transplantation. Dig Dis Sci. 2016;61:1178–85.PubMedCrossRefGoogle Scholar
  34. 34.
    Fridell JA, Bond GJ, Mazariegos GV, et al. Liver transplantation in children with cystic fibrosis: a long-term longitudinal review of a single center’s experience. J Pediatr Surg. 2003;38:1152–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Molmenti EP, Squires RH, Nagata D, et al. Liver transplantation for cholestasis associated with cystic fibrosis in the pediatric population. Pediatr Transplant. 2003;7:93–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Ikegami T, Sanchez EQ, Uemura T, et al. Liver transplantation for cystic fibrosis in adults. Surg Today. 2008;38:26–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Kelly E, Greene CM, Carroll TP, et al. Alpha-1 antitrypsin deficiency. Respir Med. 2010;104:763–72.PubMedCrossRefGoogle Scholar
  38. 38.
    Topic A, Alempijevic T, Milutinovic AS, Kovacevic N. Alpha-1-antitrypsin phenotypes in adult liver disease patients. Ups J Med Sci. 2009;114:228–34.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Chappell S, Hadzic N, Stockley R, et al. A polymorphism of the alpha1-antitrypsin gene represents a risk factor for liver disease. Hepatology. 2008;47:127–32.PubMedCrossRefGoogle Scholar
  40. 40.
    Stoller JA, Aboussouan A. A review of α1 antitrypsin deficiency. Am J Respir Crit Care Med. 2012;185:246–59.PubMedCrossRefGoogle Scholar
  41. 41.
    Lindblad D, Blomenkamp K, Teckman J. Alpha-1-antitrypsin mutant Z protein content in individual hepatocytes correlates with cell death in a mouse model. Hepatology. 2007;46:1228–35.PubMedCrossRefGoogle Scholar
  42. 42.
    Mahadeva R, Chang WS, Dafforn TR, et al. Heteropolymerization of S, I, and Z alpha1-antitrypsin and liver cirrhosis. J Clin Invest. 1999;103:999–1006.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Hinds R, Hadchouel A, Shanmugham NP, Al-Hussaini A, et al. Variable degree of liver involvement in siblings with PiZZ alpha-1-antitrypsin deficiency-related liver disease. J Pediatr Gastroenterol Nutr. 2006;43:136–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Bowlus CL, Willner I, Zern MA, et al. Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiency. Clin Gastroenterol Hepatol. 2005;3:390–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Tonelli AR, Rouhani F, Li N, et al. Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank. Int J Chron Obstruct Pulmon Dis. 2009;4:443–52.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Meyer CA, White CS, Sherman KE. Diseases of the hepatopulmonary axis. Radiographics. 2000;20:687–98.PubMedCrossRefGoogle Scholar
  47. 47.
    Curtis JR, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis. 2010;69:43–7.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Sokolove J, Strand V, Greenberg JD, et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69(9):1612–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Jones DE. Pathogenesis of primary biliary cirrhosis. J Hepatol. 2003;39:639–48.PubMedCrossRefGoogle Scholar
  50. 50.
    Kaplan MM. Primary biliary cirrhosis. N Engl J Med. 1996;335:1570–80.PubMedCrossRefGoogle Scholar
  51. 51.
    Liu B, Zhang FC, Zhang ZL, et al. Interstitial lung disease and Sjögren’s syndrome in primary biliary cirrhosis: a causal or casual association? Clin Rheumatol. 2008;27:1299–306.PubMedCrossRefGoogle Scholar
  52. 52.
    Neuhauser M, Bjornsson E, Treeprasertsuk S, et al. Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis. Am J Gastroenterol. 2010;105:345–53.PubMedCrossRefGoogle Scholar
  53. 53.
    Shen M, Zhang F, Zhang X. Primary biliary cirrhosis complicated with interstitial lung disease: a prospective study in 178 patients. J Clin Gastroenterol. 2009;43:676–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Kerkar N, Yanni G. “De Novo” and “recurrent” autoimmune hepatitis after liver transplantation: a comprehensive review. J Autoimmun. 2016;16:17–24.  https://doi.org/10.1016/j.jaut.2015.08.017.CrossRefGoogle Scholar
  55. 55.
    Schramm C, Bubenheim M, Adam R, et al. European liver intestine transplant association. Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry. Liver Transpl. 2010;16:461–9.PubMedGoogle Scholar
  56. 56.
    Silveira MG, Talwalkar JA, Lindor KD, Wiesner RH. Recurrent primary biliary cirrhosis after liver transplantation. Am J Transplant. 2010;10:720–6.PubMedCrossRefGoogle Scholar
  57. 57.
    Torring PM, Larsen MJ, Kiedsen AD, et al. Global gene expression of telangectisial tissue from patients with hereditary telangiectasia. Microvasc Res. 2015;99:118–26.PubMedCrossRefGoogle Scholar
  58. 58.
    Buonamico P, Suppressa P, Lenato GM, et al. Liver involvement in a large cohort of patients with hereditary hemorrhagic telangiectasia: echo-color-Doppler vs multislice computed tomography study. J Hepatol. 2008;48:811–20.PubMedCrossRefGoogle Scholar
  59. 59.
    Memeo M, Stabile Ianora AA, et al. Hereditary haemorrhagic telangiectasia: study of hepatic vascular alterations with multi-detector row helical CT and reconstruction programs. Radiol Med. 2005;109:125–38.PubMedGoogle Scholar
  60. 60.
    Garcia-Tsao G. Liver involvement in hereditary hemorrhagic telangiectasia (HHT). J Hepatol. 2007;46:499–507.PubMedCrossRefGoogle Scholar
  61. 61.
    Rozenberg D, Leek E, Faughnan ME. Prevalence and nature of dyspnea in patients with hereditary hemorrhagic telangiectasia [HHT]. Respir Med. 2015;109:768–77.PubMedCrossRefGoogle Scholar
  62. 62.
    Cottin V, Plauchu H, Bayle JY, et al. Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. Am J Respir Crit Care Med. 2004;169:994–1000.PubMedCrossRefGoogle Scholar
  63. 63.
    Faughnan ME, Granton JT, Young LH. The pulmonary vascular complications of hereditary haemorrhagic telangiectasia. Eur Respir J. 2009;33:1186–94.PubMedCrossRefGoogle Scholar
  64. 64.
    Epperla N, Hocking W. Blessing for the bleeder bevacizumab in hereditary hemorrhagic telangiectasia. Clin Med Res. 2015;13:32–5.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Lerut J, Orlando G, Adams R, et al. Liver transplantation for hereditary hemorrhagic telangiectasia: reprot of the European liver transplant registry. Ann Surg. 2006;244:854–62.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Gur C, Ilan Y, Shibolet O. Hepatic hydrothorax–pathophysiology, diagnosis and treatment—review of the literature. Liver Int. 2004;24(4):281.PubMedCrossRefGoogle Scholar
  67. 67.
    Sese E, Xiol X, Castellote J, et al. Low complement levels and opsonic activity in hepatic hydrothorax: its relationship with spontaneous bacterial empyema. J Clin Gastroenterol. 2003;36:75–7.PubMedCrossRefGoogle Scholar
  68. 68.
    Ferrante D, Arguedas MR, Cerfolio RJ, et al. Video-assisted thoracoscopic surgery with talc pleurodesis in the management of symptomatic hepatic hydrothorax. Am J Gastroenterol. 2002;97:3172–5.PubMedCrossRefGoogle Scholar
  69. 69.
    Ditah IC, Bawardy BF, Saberi B, et al. Transjugular intrahepatic portosystemic stent shunt for medically refractory hepatohydrothorax: a systematic review and cumulative meta-analysis. Wrold J Hepatol. 2015;13:1797–806.CrossRefGoogle Scholar
  70. 70.
    Almaslmani M, Derbala MF, Albozom I, et al. Bronchiolitis obliterans organizing pneumonia associated with Pneumocystis jiroveci infection in orthotopic liver transplantation. Transpl Infect Dis. 2008;10:339–42.PubMedCrossRefGoogle Scholar
  71. 71.
    Witte L, Rupp J, Heyer P, et al. Fibrosing alveolitis with hepatitis C-related cryoglobulinemia. Dtsch Med Wochenschr. 2008;133:709–12.PubMedCrossRefGoogle Scholar
  72. 72.
    Howard L, Gopalan D, Griffiths M, Mahadeva R. Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate. Chest. 2006;129:1718–21.PubMedCrossRefGoogle Scholar
  73. 73.
    Carrillo-Esper R, González-Avila D, Uribe-Ríos M, Méndez-Sánchez N. Interstitial pneumonitis associated with pegylated interferon alpha-2b therapy for chronic hepatitis C: case report. Ann Hepatol. 2008;7:87–90.PubMedGoogle Scholar
  74. 74.
    Krowka MJ. Hepatopulmonary syndrome and portopulmonary hypertension: implications for liver transplantation. Clin Chest Med. 2005;26:587–97.PubMedCrossRefGoogle Scholar
  75. 75.
    Colle IO, Moreau R, Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology. 2003;37:401–9.PubMedCrossRefGoogle Scholar
  76. 76.
    Thenappan T, Ryan JJ, Archer SL. Evolving epidemiology of pulmonary arterial hypertension. Am J Crit Care Med. 2012;186:707–9.CrossRefGoogle Scholar
  77. 77.
    Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;34:2493–537.Google Scholar
  78. 78.
    Kim WR, Krowka MJ, Plevak DJ, et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl. 2000;6:453–8.PubMedCrossRefGoogle Scholar
  79. 79.
    D’Alto M, Romeo E, Argiento P, et al. Accuracy and precision of echocardiography versus right heart catheterization for the assessment of pulmonary hypertension. Int J Cardiol. 2013;168:4058–62.PubMedCrossRefGoogle Scholar
  80. 80.
    Roberts KE, Fallon MB, Krowka MJ, et al. Pulmonary Vascular Complications of Liver Disease Study Group. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med. 2009;179:835–42.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Ramsay M. Portopulmonary hypertension and right heart failure in patients with cirrhosis. Curr Opin Anaesthesiol. 2010;23:145–50.CrossRefPubMedGoogle Scholar
  82. 82.
    Porres-Aguilar M, Zuckerman MJ, Figueroa-Casas JB, Krowka MJ. Portopulmonary hypertension: state of the art. Ann Hepatol. 2008;7:321–30.PubMedGoogle Scholar
  83. 83.
    Ghofrani HA, Humbert M. The role of combination in managing pulmonary arterial hypertension. Eur Respir Rev. 2014;134:469–75.CrossRefGoogle Scholar
  84. 84.
    Swanson KL, Wiesner RH, Nyberg SL, et al. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant. 2008;8:2445–53.CrossRefPubMedGoogle Scholar
  85. 85.
    Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol. 1991;17:492–8.PubMedCrossRefGoogle Scholar
  86. 86.
    Le Pavec J, Souza R, Herve P, et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med. 2008;178:637–43.PubMedCrossRefGoogle Scholar
  87. 87.
    Goldberg DS, Batra S, Sahay S, et al. MELD exceptions for portopulmonary hypertension. Current policy and future implications. Am J Transplant. 2014;9:2081–7.CrossRefGoogle Scholar
  88. 88.
    Fallon MB, Mulligan DC, Gish RG, Krowka MJ. Model for end-stage liver disease (MELD) exception for hepatopulmonary syndrome. Liver Transpl. 2006;12(12 Suppl 3):S105–7.PubMedCrossRefGoogle Scholar
  89. 89.
    Rafanan AL, Maurer J, Mehta AC, Schilz R. Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol. Chest. 2000;118:1497–500.PubMedCrossRefGoogle Scholar
  90. 90.
    Koneru B, Ahmed S, Weisse AB, et al. Resolution of pulmonary hypertension of cirrhosis after liver transplantation. Transplantation. 1994;58:1133–5.PubMedCrossRefGoogle Scholar
  91. 91.
    Pascasio JM, Grilo I, Lopez-Pardo FJ, et al. Prevalence and severity of Hepatopulmonary syndrome and its influence on survival on cirrhotic patients evaluated for transplantation. Am J Transplant. 2014;14:1391–9.PubMedCrossRefGoogle Scholar
  92. 92.
    Fierro Alanis MP, Bastón Rey I, Nieves-Maldonado S. Platypnea-orthodeoxia syndrome: Importance of patient position for correct diagnosis at the time of (99m)Tc-MAA injection. Rev Esp Med Nucl Imagen Mol. 2015;34:261–3.PubMedGoogle Scholar
  93. 93.
    El-Shabrawi MH, Omran S, Wageeh S, et al. 99mTechnetium-macroaggregated albumin perfusion lung scan versus contrast enhanced echocardiography in the diagnosis of the hepatopulmonary syndrome in children with chronic liver disease. Eur J Gastroenterol Hepatol. 2010;22(8):1006–12.PubMedCrossRefGoogle Scholar
  94. 94.
    Rodriguez-Roisin R, Roca J, Agusti AG, et al. Gas exchange and pulmonary vascular reactivity in patients with liver cirrhosis. Am Rev Respir Dis. 1987;135:1085–92.PubMedGoogle Scholar
  95. 95.
    Gómez FP, Martínez-Pallí G, Barberà JA, et al. Gas exchange mechanism of orthodeoxia in hepatopulmonary syndrome. Hepatology. 2004;40:660–6.PubMedCrossRefGoogle Scholar
  96. 96.
    Degano B, Mittaine M, Hervé P, et al. Nitric oxide production by the alveolar compartment of the lungs in cirrhotic patients. Eur Respir J. 2009;34:138–44.PubMedCrossRefGoogle Scholar
  97. 97.
    Gómez FP, Barberà JA, Roca J, et al. Effects of nebulized N(G)-nitro-L-arginine methyl ester in patients with hepatopulmonary syndrome. Hepatology. 2006;43:1084–91.PubMedCrossRefGoogle Scholar
  98. 98.
    Tang L, Luo B, Patel RP, et al. Modulation of pulmonary endothelial endothelin B receptor expression and signaling: implications for experimental hepatopulmonary syndrome. Am J Physiol Lung Cell Mol Physiol. 2007;292:L1467–72.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Krowka MJ, Mandell MS, Ramsay MA, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl. 2004;10:174–82.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: impact of liver transplantation. Hepatology. 2005;41:1122–9.PubMedCrossRefGoogle Scholar
  101. 101.
    Arguedas MR, Abrams GA, Krowka MJ, Fallon MB. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology. 2003;37:192–7.CrossRefPubMedGoogle Scholar
  102. 102.
    Benítez C, Arrese M, Jorquera J, et al. Successful treatment of severe hepatopulmonary syndrome with a sequential use of TIPS placement and liver transplantation. Ann Hepatol. 2009;8:71–4.PubMedGoogle Scholar
  103. 103.
    De BK, Sen S, Biswas PK, et al. Occurrence of hepatopulmonary syndrome in Budd-Chiari syndrome and the role of venous decompression. Gastroenterology. 2002;122:897–903.PubMedCrossRefGoogle Scholar
  104. 104.
    Nayyar D, Man HS, Granton J, et al. Proposed management algorithm for severe hypoxemia after liver transplantation in the hepatopulmonary syndrome. Am J Transplant. 2015;15:903–13.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Schiffer E, Majno P, Mentha G, et al. Hepatopulmonary syndrome increases the postoperative mortality rate following liver transplantation: a prospective study in 90 patients. Am J Transplant. 2006;6:1430–7.PubMedCrossRefGoogle Scholar
  106. 106.
    Taille C, Cadranel J, Bellocq A, et al. Liver transplantation for hepatopulmonary syndrome: a ten year experience in Paris, France. Transplantation. 2003;75:1482–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of AnesthesiologyUniversity of ColoradoAuroraUSA
  2. 2.Department of SurgeryHokkaido UniversitySapporaJapan

Personalised recommendations